Source: International Congress 2018 – Organoids and pluripotent stem cells



Rating:

Share or cite this content

Citations should be made in the following way:
J. Beekman (Utrecht, Netherlands). Intestinal organoids as ex vivo models for personalised medicine in cystic fibrosis. International Congress 2018 – Organoids and pluripotent stem cells

Member's Comments

No comment yet.

Related content which might interest you: Intestinal organoids to model cystic fibrosis Source: Eur Respir J, 54 (1) 1802379; 10.1183/13993003.02379-2018 Year: 2019 Advanced cell culture techniques and personalised medicine for cystic fibrosis Source: International Congress 2015 – Respiratory research in the Netherlands Year: 2015 Individual treatment of cystic fibrosis by using intestinal organoids Source: International Congress 2015 – Advancing therapies for cystic fibrosis Year: 2015 Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis Source: Eur Respir J, 57 (1) 1902426; 10.1183/13993003.02426-2019 Year: 2021 Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung Year: 2012 The cystic fibrosis airway milieu enhances rescue of F508del in a pre-clinical model Source: Eur Respir J, 52 (6) 1801133; 10.1183/13993003.01133-2018 Year: 2018 LSC Abstract – A human lung explant model of fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis Source: International Congress 2016 – Molecular immunology of the lung Year: 2016 Unravelling specific mechanisms of wound healing and pulmonary fibrosis in human ex vivo lung tissue slices Source: International Congress 2018 – Pulmonary fibrosis: from models to patients Year: 2018 Is cystic fibrosis the hemi-neglected part of respiratory medicine? Source: Virtual Congress 2021 – CCC Thoracic oncology Year: 2021 Lung lymphoid neogenesis in cystic fibrosis: a model of adaptive responses to bacteria? Source: Eur Respir J , 49 (4)  1700380; DOI: 10.1183/13993003.00380-2017 Year: 2017 Characterisation of an ex vivo model of human airway epithelium Source: International Congress 2019 – Novel insights from in vitro and in vivo models of lung disease Year: 2019 Personalised medicine for cystic fibrosis: treating the basic defect Source: Eur Respir Rev 2013; 22: 3-5 Year: 2013 Measuring CFTR function in respiratory epithelial cell cultures: step to individualize treatments in cystic fibrosis? Source: Virtual Congress 2021 – Monitoring of lung disease and CFTR function in children with cystic fibrosis Year: 2021 Cystic fibrosis and intestinal organoids Source: ERN-LUNG 2021: Cystic fibrosis and intestinal organoids Year: 2021 Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo Source: Eur Respir J, 50 (2) 1602367; 10.1183/13993003.02367-2016 Year: 2017 Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy Source: Breathe, 17 (4) 210112; 10.1183/20734735.0112-2021 Year: 2021 Use of biomaterials to tissue engineer 3D models with lung organoids for in-vitro disease modelling Source: Virtual Congress 2020 – Lung epithelial development and repair in three-dimensions Year: 2020 Novel therapeutics for cystic fibrosis Source: ERS Webinar 2020: Novel therapeutics for cystic fibrosis Year: 2020